FindTrial
Sign In

The clinical outcome of different doses of vagina progesterone (Utrogestan) used for ovarian stimulation in normalovulatory women: a prospective, randomized, controlled trial

The clinical outcome of different doses of vagina progesterone (Utrogestan) used for ovarian stimula

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-OOC-14005277
Enrollment
Unknown
Registered
2014-09-24
Start date
2014-09-25
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

high dose group:Utrogestan 200mg/d
low dose group:Utrogestan 100mg/d

Sponsors

Shanghai Ninth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: infertility women, aged 20-40 years, normal mentrual cycle(23-35 days), tubal or male factors, basal FSH<10IU/L, antral follicle counts more than 4.

Exclusion criteria

Exclusion criteria: PCOS, endometrosis grade 3 or higher, documented ovarian failure, and any contraindications to ovarian stimulation treatment.

Design outcomes

Primary

MeasureTime frame
Rate of oocytes retrieved;number of fertilized oocytes;Percent of super embryos based all oocyte;number of mature oocytes;occurrence of a premature LH surge;—

Secondary

MeasureTime frame
clinical pregnancy rate;—

Countries

China

Contacts

Public ContactYonglun Fu
shfuyonglun@sina.cn+86 13917547302

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 11, 2026